Notes / Company

Emcure Pharmaceuticals Ltd.

EMCURE BSE 544210 ISIN INE168P01015 Pharmaceuticals

Fundamentals

Market cap: ₹35,664 cr
P/E: 38.58×
ROE: 15.32%
Debt / equity: 0.16
Div yield: 0.20%
52-week range: 1228.90 — 1902.70

Research on Tijori Finance

Company snapshot

Emcure Pharmaceuticals Ltd.

Pharmaceuticals

₹35,294 cr

P/E 38.18×

Latest quarter · Mar 2026

Sales₹2,470 cr

Net profit₹244 cr

Op. margin+19.4%

EPS₹12.84

Strength & growth

Debt / equity0.16×

Current ratio1.71×

The timeline — 1 note on Emcure Pharmaceuticals Ltd.

July 2026

20 Jul 26 · 4:20 PM IST Lead

Lead · Large cap

Emcure's semaglutide gets CDSCO nod for fatty liver disease MASH

India's first GLP-1 receptor agonist cleared for non-cirrhotic MASH with moderate to advanced fibrosis. Poviztra adds a major new indication to its existing approvals for weight management, CVD, and adolescent obesity.

Verify on exchange BSE filings for EMCURE NSE filings for EMCURE Tijori Finance company page